Bayer shares enter a make-or-break stretch as investors await two court developments that could determine whether the company can contain Roundup litigation losses.
The first is a US Supreme Court decision on Bayer’s bid to block tens of thousands of claims alleging Monsanto’s Roundup should have carried a cancer warning label.
Around the same time, a fairness hearing is scheduled on a separate $7.25 billion class-action settlement meant to resolve current and future Roundup cancer claims.
The stakes are high because the litigation has already wiped more than $60 billion from Bayer’s market value since its Monsanto acquisition eight years ago.
Can two looming US court decisions finally end Bayer's multi-billion dollar Roundup nightmare?
With top scientific bodies clashing, who truly gets to decide if Roundup is a cancer risk?
Can a presidential order shield Bayer from thousands of lawsuits, regardless of court rulings?
Bayer’s $7.25 Billion Roundup Settlement and Supreme Court Showdown: The Future of Glyphosate Litigation
Overview
As of June 2026, the legal fight over Monsanto's Roundup weedkiller has reached a turning point. Bayer, which acquired Monsanto, faces thousands of lawsuits from people claiming Roundup causes non-Hodgkin lymphoma. The U.S. Supreme Court is about to decide if federal law should protect Bayer from state lawsuits, a ruling that could reshape the entire case. At the same time, Bayer is offering a $7.25 billion settlement to resolve many claims, while insisting that federal regulations already cover product safety and labeling. The outcome will have major legal and financial impacts for everyone involved.